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Introduction
• DLBCL has poor survival with current 1st and 2nd line
therapies
• Anti-CD19 CAR T cells (tisagenlecleucel) have a ~50%
complete response rate in r/r cases
– BUT costs ~$475,000

• Objective: correlate response to CAR T cell to the
bulkiness of tumor burden

Introduction
• Previous research showed increased risk of adverse
effects (i.e. tumor lysis) with increased tumor burden
• Currently no data predicting response based on
baseline imaging
• Could help determine best candidates to receive this
high-cost therapy

Objectives
& Hypothesis
• Research Question
– Does average index lesion area correlate to
response outcome in r/r DLBCL treated with CAR T
cells?

• Hypothesis
– Higher average index lesion area correlates to
increased incidence of progressive disease
following r/r DLBCL treated with CAR T cells.

Approach & Results
• Secondary data analysis
• Population: 20 r/r DLBCL pts treated with anti-CD19
chimeric antigen receptor T cells
• No intervention (data analysis)
• Comparison: low vs high tumor bulk
• Outcome: Response to tisagenlecleucel
• Data source and collection: index lesions on baseline CT
scan per Chesson criteria, response outcomes

Approach & Results
• Analysis
– ROC AUC, Chi square (a=0.05)

• Findings
– ROC AUC = 68%
• Aggregate measure of metric performance
– Cutoff value of 7 cm2
• Sensitivity = 100%, FPR = 50%
• Next lowest FPR was 33% with sensitivity of 62.5% at
4cm2 cutoff.
– Chi square = 5.71 (p=0.017)

Conclusions
• Low tumor bulk (<7cm2) showed statistically
significant correlation with higher response rate to
tisagenlecleucel
– Need further data to increase confidence in result

• Demonstrates potential for clinical utility in
treatment decisions for r/r DLBCL

Future Directions
• Repeat analysis with larger sample size using
non-clinical trial patients
• Assess other factors that could predict
outcome (cytokine levels, peak CAR T cell
levels)
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